Abstract
Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor to treat hormone-positive, HER2-negative metastatic breast cancer. Severe skin toxicities are rare but important adverse events associated with these agents. Early detection of severe forms of skin lesions is crucial to permit the immediate discontinuation of palbociclib in order to avoid unacceptable risk level in the form of severe cutaneous toxicities like Steven-Johnson Syndrome. In such cases, palbociclib should be abruptly discontinued and an early aggressive support should be initiated. We here present a case of 50-year-old Caucasian female, who developed acute onset blistering skin lesions one to two weeks after she was started on palbociclib. We sought to report this case given the unusual toxicity and to emphasize the importance of identifying the acute onset of blistering skin lesions, regardless of their extension, should prompt awareness of their potential severity.
Highlights
Palbociclib is a well-known cyclin kinase 4/6 inhibitor used in metastatic hormone receptor-positive breast cancer
Neutropenia, anemia, thrombocytopenia, nausea, diarrhea, and skin rash are some of the reported adverse effects (AEs)
More severe skin rash was less than 1% so far in the clinical literature as we found only one case of severe cutaneous toxicity presented as Stevens-Johnson syndrome [1]
Summary
Palbociclib is a well-known cyclin kinase 4/6 inhibitor used in metastatic hormone receptor-positive breast cancer. It is most commonly used as a first-line treatment in conjunction with aromatase inhibitors. Acute bullous skin rash is very rare and warrants immediate discontinuation of palbociclib We report this case of acute bullous skin rash in a patient who was recently started on palbociclib for metastatic hormone receptor-positive breast cancer. A 50-year-old female was diagnosed with metastatic hormone receptor-positive breast cancer She initially presented with hip pain on the right side. The cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib was added to the anastrazole Two weeks later, she presented to her local oncologist office with a skin rash on her lower extremities. Biopsy of the lesions could not be obtained due to personal reasons of the patient
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
